Last edition
News about "synthetic royalty funding agreement "
Syndax Signs USD 350 Million Royalty Funding Deal with Royalty Pharma for Niktimvo
Under the terms of the agreement, Syndax received an upfront payment of USD 350 million in exchange for a 13.8 percent royalty on US net sales of Niktimvo.
Synthetic Royalty Funding Agreement | 06/11/2024 | By Aishwarya | 113
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members